Statin-Induced Autoimmune Necrotizing Myopathy.

J Prim Care Community Health

Reading Hospital, West Reading, PA, USA.

Published: August 2021

Statin therapy is a widely prescribed medication class for hypercholesterolemia. In statin-induced autoimmune myopathy, genetically predisposed and at-risk patients can develop antibodies against hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the key enzyme in the production of cholesterol. As a result, an autoimmune reaction causing weakness, myalgia, with possible severe rhabdomyolysis, renal failure, and myonecrosis also can occur. A 73-year-old female presented to clinic with myalgia and fatigue. She was on atorvastatin 20 mg/day for over 1 year, which she stopped 1 week prior to her initial presentation. Patient did experience rhabdomyolysis as well as a transaminitis. She underwent an autoimmune workup which was positive for HMG-CoA reductase antibodies. Patient was initially treated on a prednisone taper, starting dose 50 mg/day. Without remission of symptoms, methotrexate 15 mg/week was initiated.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255573PMC
http://dx.doi.org/10.1177/21501327211028714DOI Listing

Publication Analysis

Top Keywords

statin-induced autoimmune
8
autoimmune necrotizing
4
necrotizing myopathy
4
myopathy statin
4
statin therapy
4
therapy prescribed
4
prescribed medication
4
medication class
4
class hypercholesterolemia
4
hypercholesterolemia statin-induced
4

Similar Publications

Statin-Induced Necrotizing Autoimmune Myopathy: Diagnosis and Treatment Approach.

JCEM Case Rep

December 2024

Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA.

The widespread use of statins for cardiovascular diseases has unveiled a new subset of inflammatory myopathy, immune-mediated necrotizing myopathy (IMNM). We describe below an unusual case of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy. A 64-year-old male individual with type 2 diabetes, hyperlipidemia, and coronary artery disease presented with progressive proximal muscle weakness and pain for 3 months.

View Article and Find Full Text PDF

Statin-induced necrotizing autoimmune myopathy (SINAM) is a rare, disabling, and potentially life-threatening complication of statin use. Although not fully understood, a prevailing hypothesis proposes that statins induce molecular changes in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), leading to the formation of anti-HMGCR antibodies. The subsequent myofibre necrosis is expressed as progressive and persistent proximal muscle weakness and elevated creatine kinase (CK) levels.

View Article and Find Full Text PDF

Statins, commonly used for hyperlipidemia and more importantly having proven efficacy in lowering cardiovascular risk, are a very popular class of medications. Side effects are usually mild, and the class as a whole is generally well-tolerated by patients. However, one rare and more serious side effect is statin-induced autoimmune necrotizing myopathy.

View Article and Find Full Text PDF
Article Synopsis
  • - Statins are effective for cholesterol control but can lead to a rare and serious condition called statin-induced necrotizing autoimmune myopathy (SINAM).
  • - The report discusses SINAM's epidemiology, symptoms, diagnostic challenges, and evolving theories about its causes and treatments.
  • - Emphasizing the importance of early diagnosis and a multidisciplinary approach, the article also calls for more research to improve understanding and management of SINAM.
View Article and Find Full Text PDF

Immune-mediated necrotizing myopathy (IMNM) is a rare type of auto-immune myositis, characterized by symmetric muscle pain, proximal weakness, elevated serum CK levels and pathologic findings of necrotized muscle fibers. IMNM may be seronegative, associated with anti-signal recognition particle (SRP) antibodies or anti-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) antibodies, the last widely related with statin use. This last entity affects only 2 to 3 of 100,000 patients under statins.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!